Related Experiment Video
Updated: Aug 9, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
Role of cognitive testing in disease modifying AD trials
1Department of Psychiatry and Neuropsychology, University of Maastricht, The Netherlands.
Abstract:
Cognitive impairment is a key feature of Alzheimer's disease (AD). Cognitive performance will therefore be an important outcome measure in disease modifying drug trials. However, cognitive assessment also has several limitations such as a large inter and intra individual variability and floor and ceiling effects. To reduce the effect of these limitations on the accuracy with which drug-related changes can be detected, it is proposed to analyse cognitive change using a slope analysis. In addition, it is suggested to use as the main outcome measure for cognitive impairment a neuropsychological compound score that is based on a z-score transformation of a number of well-validated tests. The selection of these tests would depend on a number of study characteristics such as the inclusion criteria and the length of follow-up.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Clinical Trials: Overview
Pharmacogenomics: Identification of New Drug Targets
Clinical Trials
There are four phases in a clinical trial. A phase one...

